Alliance Pharma Share Discussion Threads

[mattboxy] 30/4/2024 19:58

Wherever you see Blackhorse push this run for the hills.

[mattboxy] 30/4/2024 19:57

Don't invest here invest in a quality company with shares that go up!

[mattboxy] 30/4/2024 19:57

Money moving out of here anywhere but here!

[blackhorse23] 30/4/2024 09:25

That's the full year results publishing next week

[wad collector] 30/4/2024 09:14

Why keep posting the old TU from January?

[maverick67] 30/4/2024 08:32

Still she on a down... moved money to card

[blackhorse23] 30/4/2024 07:46

Full Year Trading Update Strong revenues on H2 recovery, leverage reduced Alliance Pharma plc (AIM: APH), the international healthcare group, announces its trading update for the year ended 31 December 2023 (the "Period"), ahead of the announcement of the Group's audited results in March 2024, which are anticipated to be in line with market expectations.Financial summaryThe Group delivered record see-through1 revenues in the Period of £182.7m (FY22: £172.0m), up 6% versus the prior period and up 7% at constant exchange rates ("CER"). Excluding sales from ScarAway and the US rights to Kelo-Cote in Q1 23, both acquired in March 2022 (the "US Acquisition"), like-for-like see-through revenues increased 6% CER. Continued strong consumer demand, particularly in China, drove significant recovery in Kelo-Cote franchise revenues in H2, leading to FY23 revenues of £63.2m, up 29% CER (FY22: £50.0m). Nizoral revenues increased 3% CER to £21.7m (FY22: £21.8m) whilst Amberen revenues declined 6% CER on an underlying basis (excluding the leading discount store account that was lost in 2022) and decreased 25% CER to £11.2m (FY22: £14.9m) on a reported basis. With Other Consumer brands up 5% CER to £40.3m (FY22: £38.4m), total see-through Consumer Healthcare revenues increased 11% CER to £136.4m. Prescription Medicine revenues were stable at £46.3m (FY22: £46.8m), reflecting a strong recovery in H2 as expected, as previously out of stock products became available. Underlying profit for the Period is anticipated to be in-line with market expectations.

[fatfish] 30/4/2024 07:13

still going down

[blackhorse23] 29/4/2024 15:43

1 million block buy very end of trading

[blackhorse23] 29/4/2024 15:21

AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders-DIVIDEND +5% -PORTFOLIO BROADENED THROUGH ACQUISITION

[blackhorse23] 29/4/2024 13:51

115k block buying 4 times , something brewing

[blackhorse23] 29/4/2024 12:43

Buying this as much as possible before next week results

[baldrick1] 29/4/2024 10:14

Hey blackhorse are you trading this ???

[baldrick1] 29/4/2024 09:50

Could we buy this at 33p???

[blackhorse23] 29/4/2024 09:18

Back to 100p per share like last year, FY results will be good

[wad collector] 29/4/2024 09:14

Shall I remind you of some of your previous predictions here?

[blackhorse23] 29/4/2024 08:41

Next week will be double from here , bullish FY results

[blackhorse23] 29/4/2024 08:01

Bought 47800 shares @ 34.70p , average down , EXCELLENT OPPORTUNITY

[maverick67] 27/4/2024 21:01

Yep going to be tin hats time....

[trustman] 26/4/2024 07:45

Date given, May 8th.
If there is nothing wrong with remittances from China and debt is decreasing AND the CMA sanctions are diluted this could be quite interesting!

[blackhorse23] 26/4/2024 07:18

In total 4 weeks delay now

[wad collector] 25/4/2024 07:50

Worse than that I'm afraid, Dec14.

[kpe] 25/4/2024 07:17

Hard hat time. 3 year low coming up.

[blackhorse23] 24/4/2024 16:07

What did you email?

[justiceforthemany] 24/4/2024 15:09

Email Investor Relations
[e-mail]